These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20189083)

  • 1. Blood pressure lowering with valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):85-91. PubMed ID: 20189083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
    Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of valsartan versus non-RAAS treatment on autoregulation of cerebral blood flow.
    Périard D; Rey MA; Casagrande D; Vesin JM; Carrera E; Hayoz D
    Cerebrovasc Dis; 2012; 34(1):78-85. PubMed ID: 22814178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
    Dong YF; Kataoka K; Tokutomi Y; Nako H; Nakamura T; Toyama K; Sueta D; Koibuchi N; Yamamoto E; Ogawa H; Kim-Mitsuyama S
    J Pharmacol Exp Ther; 2011 Nov; 339(2):358-66. PubMed ID: 21807884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic influences of losartan on the brain in hypertensive patients.
    Oku N; Kitagawa K; Imaizumi M; Takasawa M; Piao R; Kimura Y; Kajimoto K; Matsumoto M; Hori M; Hatazawa J
    Hypertens Res; 2005 Jan; 28(1):43-9. PubMed ID: 15969254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
    Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
    Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
    Savoia C; Touyz RM; Volpe M; Schiffrin EL
    Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke.
    Matsumoto S; Shimodozono M; Miyata R; Kawahira K
    Int J Neurosci; 2010 May; 120(5):372-80. PubMed ID: 20402577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease.
    Higuchi T; Abletshauser C; Nekolla SG; Schwaiger M; Bengel FM
    Microcirculation; 2007; 14(8):805-12. PubMed ID: 17907015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.
    Matsumoto S; Shimodozono M; Miyata R; Kawahira K
    Hypertens Res; 2009 Nov; 32(11):1015-21. PubMed ID: 19745828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
    Weisser B; Vetter H; Mengden T
    Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
    Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
    Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valsartan improves the lower limit of cerebral autoregulation in rats.
    Takada J; Ibayashi S; Ooboshi H; Ago T; Ishikawa E; Kamouchi M; Kitazono T; Iida M
    Hypertens Res; 2006 Aug; 29(8):621-6. PubMed ID: 17137218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.